An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically or cytologically confirmed carcinoma of the colon and/or rectum with evidence of metastases * At least one measurable metastatic lesion (as per RECIST criteria) * Life expectancy of \> 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Adequate hematological, renal and liver function Exclusion Criteria: * Prior chemotherapy for metastatic disease * Clinically significant cardiovascular disease * Ongoing treatment with aspirin (325 mg/day) or other medications known to predispose for gastrointestinal ulceration * Participation in an investigational trial in the previous 3 months * Pregnant or lactating women * History of thrombotic or haemorrhagic disorders * Evidence of bleeding diathesis or coagulopathy * Uncontrolled hypertension * Known hypersensitivity to Avastin and any of its excipients, or any of the chemotherapies * Evidence of any disease or disorder that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications